A comprehensive guide to psychopharmacological well-being — from classical antidepressants to psychedelic-assisted therapy, novel neuroplasticity agents, and the frontiers of mood genomics.
The first Good Drug Guide appeared on biopsychiatry.com during the early internet era, when fluoxetine was still controversial and the idea of pharmacological well-being enhancement was considered either utopian fantasy or moral transgression. Much has changed. Ketamine therapy is now mainstream. Psilocybin has been legalised for therapeutic use in several jurisdictions. A new generation of drugs targets not just the acute symptoms of depression but its biological substrate — the mechanisms governing hedonic set-point, neuroplasticity, and the architecture of positive affect.
This 2026 edition is a comprehensive revision. It covers all major classes of psychoactive agents relevant to mood, anxiety, cognition, and hedonic tone, from well-established antidepressants to experimental TAAR1 agonists, kappa-opioid antagonists, and neuroactive steroids. It also looks ahead to the genomic revolution in mood medicine — the possibility, now within the horizon of credibility, of editing the hedonic set-point at source.
The guide does not pretend to be a substitute for medical advice. It is written for the intelligent lay reader who wants to understand the science of mood pharmacology: what drugs do, how well they work, their limitations, and what is coming next. It is written from a perspective that takes seriously the moral imperative to reduce suffering and increase well-being — not just in clinical populations, but potentially across all sentient life.
This guide is for educational purposes only. It does not constitute medical advice. Drug interactions, individual neurochemistry, and clinical context vary enormously. Nothing described here should be commenced, discontinued, or modified without consultation with a qualified healthcare provider. Legal status of controlled substances varies by jurisdiction.
Mood is not a single thing. It is the emergent property of at least a dozen interacting neurochemical systems, distributed across the brainstem, limbic system, prefrontal cortex, and their bidirectional projections. Understanding how drugs affect mood requires a working map of this landscape.
The monoamine hypothesis — formulated in the 1960s, refined ever since — holds that mood disorders involve dysregulation of monoamine neurotransmission. Serotonin (5-HT) modulates affect, impulsivity, and social behaviour. Its cell bodies in the raphe nuclei project broadly across the cortex and limbic system. Dopamine governs reward anticipation, motivation, and the experience of wanting; its mesolimbic pathway is the substrate of incentive salience. Noradrenaline mediates arousal, stress reactivity, and, crucially, the physical energy that carries emotional valence.
The monoamine hypothesis, while indispensable, is incomplete. SSRIs boost serotonin transmission within hours; their clinical effects take weeks. This temporal dissociation points to downstream neuroplastic processes — particularly BDNF signalling and hippocampal neurogenesis — as the proximate mechanisms of antidepressant action.
Glutamate is the brain's primary excitatory neurotransmitter. Its NMDA receptors are critical for synaptic plasticity, learning, and, it now appears, rapid mood regulation. The discovery that sub-anaesthetic ketamine — an NMDA antagonist — produces antidepressant effects within hours overturned decades of monoamine-centric thinking. The glutamate system is now understood as the master regulator of synaptic architecture, and its rapid manipulation offers a path to mood change that bypasses the slow timescale of monoamine adaptation.
GABA is the brain's primary inhibitory neurotransmitter. GABAergic tone shapes the gain of emotional circuits — insufficient GABA produces anxiety and hyperarousal; excessive GABA produces sedation. The GABA-A receptor complex, the target of benzodiazepines and neuroactive steroids, is the most important inhibitory receptor in the brain. Recent appreciation of the role of neurosteroids — endogenous GABA-A positive allosteric modulators like allopregnanolone — in mood regulation has opened a new pharmacological frontier.
Often neglected in discussions of antidepressant pharmacology, the endogenous opioid system — comprising mu, kappa, and delta receptors — is a fundamental regulator of hedonic tone. Mu receptor activation produces euphoria, analgesia, and social warmth; kappa receptor activation produces dysphoria, stress, and emotional blunting. The kappa system in particular has emerged as a major target in depression research: endogenous dynorphins, which activate kappa receptors, are elevated in chronic stress states and appear to sustain the dysphoric component of depression.
CB1 receptors, distributed throughout limbic and prefrontal regions, regulate stress resilience, fear extinction, and hedonic responsiveness. Endocannabinoid tone modulates the emotional valence of experience. THC's acute euphoric effects and the well-being effects of anandamide both operate through this system. The therapeutic potential of selective cannabinoid modulation — distinct from recreational cannabis — remains underexplored.
The hypothalamic-pituitary-adrenal axis mediates the stress response. Chronic stress elevates cortisol, which is directly toxic to hippocampal neurons and suppresses BDNF expression. Elevated inflammatory cytokines — IL-6, TNF-α, CRP — are found consistently in treatment-resistant depression and appear causally related to anhedonia. Drugs that reduce neuroinflammation (low-dose naltrexone, celecoxib, minocycline) have shown preliminary antidepressant effects, supporting the inflammatory hypothesis of depression.
The hedonic set-point is the baseline level of well-being to which an individual habitually returns following life events, both positive and negative. Identical lottery wins and paraplegia, the famous Brickman et al. data suggested, produce only transient departures from a stable affective baseline. Genetics accounts for approximately 40–50% of variance in subjective well-being, an estimate refined by decades of twin and GWAS studies.
This has profound implications for psychopharmacology. Most antidepressants do not raise the hedonic set-point; they treat acute depressive episodes by normalising aberrantly low hedonic tone. Patients often describe feeling "back to normal" rather than elevated. The question of whether pharmacology can produce genuinely supranormal positive affect — can lift the floor and the ceiling — is one of the central questions of this guide.
The emerging answer is: partially, in some people, under some conditions. Psychedelics may produce lasting increases in hedonic set-point by inducing neuroplastic reorganisation of prefrontal circuits. Opioid-based approaches may more directly target the pleasure-pain balance. Genetic interventions — particularly CRISPR-based editing of alleles associated with low hedonic tone — offer, in principle, permanent set-point elevation. That frontier is addressed in Part III.
Pharmacological well-being enhancement faces a fundamental obstacle: homeostatic adaptation. The brain responds to sustained pharmacological perturbation by adjusting receptor density, coupling efficiency, and downstream signalling to restore equilibrium. This is why benzodiazepine euphoria fades within weeks, why SSRI emotional blunting develops, and why stimulant tolerance limits long-term use.
Not all drugs produce equal tolerance. The rapid antidepressant effects of ketamine do not require daily dosing; intermittent administration preserves efficacy. Psilocybin's effects on mood may be persistent after a small number of sessions, possibly because they operate through structural changes in synaptic connectivity rather than receptor occupancy per se. Understanding the difference between functional changes (prone to adaptation) and structural changes (more stable) is key to rational psychopharmacology.
Selective serotonin reuptake inhibitors remain the most widely prescribed antidepressants globally, a position they have held since fluoxetine's approval in 1987. Their dominance owes as much to their safety profile and tolerability as to their modest-to-moderate efficacy. The canonical Cipriani meta-analysis (2018, Lancet) confirmed that all SSRIs outperform placebo in acute major depression — but the effect size is small to moderate (NNT roughly 7–9), and remission rates remain disappointingly low at around 30–40%.
The SNRIs — which additionally block noradrenaline reuptake — offer modest advantages in pain comorbidity and, for some patients, better tolerability than SSRIs. Both classes share the same delayed onset (2–6 weeks), sexual dysfunction liability, and discontinuation syndrome profile.
The most selective SSRI and, in head-to-head comparisons, consistently among the best-tolerated and most effective. The active enantiomer of citalopram. Preferred first-line agent for many psychiatrists.
The most widely prescribed antidepressant in many countries. Additional weak sigma-1 receptor agonism may contribute subtly to its effects. Broad evidence base across depression, OCD, PTSD, panic, and anxiety disorders. Activating profile can cause initial insomnia.
The original SSRI. Long half-life (and active metabolite norfluoxetine: t½ 4–16 days) makes it uniquely forgiving of missed doses and produces the mildest discontinuation syndrome. Activating. Useful in atypical depression, bulimia, PMDD. Its public biography of the 1990s still shapes cultural perceptions of antidepressants.
A potent sigma-1 receptor agonist in addition to SSRI activity — this secondary mechanism may confer neuroprotective and anxiolytic advantages. First-line for OCD. The sigma-1 agonism attracted interest during the COVID-19 pandemic for potential anti-inflammatory effects. Metabolic drug interactions via CYP1A2/CYP3A4 inhibition require caution.
The most anticholinergic SSRI — which produces sedation useful in anxious-agitated presentations but a worse side-effect profile overall (weight gain, cognitive effects, worst discontinuation syndrome of any SSRI). Still useful in specific contexts: social anxiety, PTSD with hyperarousal. Largely superseded by cleaner agents for most indications.
At low doses (75mg), acts as an SSRI. Noradrenaline reuptake inhibition emerges above 150mg, dopamine reuptake inhibition at very high doses (300mg+). The dose-dependent mechanism profile allows clinicians to titrate the pharmacological target. Particularly effective in anxious depression. Extended-release formulation preferred. Worst SNRI discontinuation syndrome.
Balanced 5-HT and NE reuptake inhibition from lower doses than venlafaxine. Particularly useful where pain is comorbid (fibromyalgia, neuropathic pain, musculoskeletal pain). Nausea on initiation is common; taking with food helps. Approved for generalised anxiety, stress urinary incontinence (as well as depression and pain disorders).
Active metabolite of venlafaxine. Linear pharmacokinetics; no CYP2D6 metabolism, making it more predictable in extensive and poor metabolisers. Modest advantages in hormonal fluctuations (vasomotor symptoms); studied in perimenopausal depression. Essentially equivalent to venlafaxine for most patients.
A persistent controversy surrounds SSRI efficacy. Irving Kirsch's meta-analyses suggested that much of the benefit over placebo was clinically insignificant in mild-moderate depression, and that only severe depression shows robust drug-placebo differences. Cipriani et al. (2018) provided a more nuanced picture: all antidepressants show genuine but modest superiority to placebo, with effect sizes (Hedges' g ≈ 0.3) that are clinically meaningful for a substantial minority. The debate is partly about what we mean by "meaningful." For individuals who respond fully, an SSRI can be life-transforming; for the majority who achieve partial response, it is a floor but not a ceiling. This is the challenge the newer agents attempt to address.
The standard SSRI side-effect profile deserves frank discussion: sexual dysfunction (delayed orgasm, reduced libido, anorgasmia) affects 40–80% of patients and is the leading cause of discontinuation; emotional blunting — a subjective dampening of affective range often described as feeling "flat" or "in a glass bubble" — affects 30–40% and represents the inverse of the clinical goal of well-being enhancement; weight gain is modest with most SSRIs (least with fluoxetine) but cumulative; discontinuation syndrome (dizziness, "brain zaps," irritability, flu-like symptoms) can be severe, particularly with paroxetine and venlafaxine.
Post-SSRI sexual dysfunction (PSSD) — persistent sexual and emotional symptoms following discontinuation — has received formal recognition and may affect a non-trivial minority. Its mechanism is uncertain but may involve epigenetic changes in serotonin receptor expression.
Monoamine oxidase inhibitors are the most efficacious antidepressants ever discovered — and the most underused. Their neglect is a medical tragedy of the first order. MAOIs consistently outperform SSRIs in treatment-resistant depression, atypical depression (with mood reactivity, hypersomnia, leaden paralysis, rejection sensitivity), and panic disorder with agoraphobia. The dietary restrictions required by classical MAOIs (tyramine avoidance to prevent hypertensive crisis) have deterred prescribing for decades — but these risks are manageable and, for many patients, a small price for a drug that works when nothing else has.
The gold standard MAOI for atypical depression and social anxiety. Irreversibly inhibits both MAO-A and MAO-B. Additional GABAergic activity (GABA-B agonism via its metabolite phenylethylidenehydrazine) may contribute to its potent anxiolytic effects. Often produces marked emotional deepening and social ease. Requires strict tyramine diet. Insomnia, orthostatic hypotension, weight gain, sexual dysfunction are common. Two-week washout required before switching to most other drugs.
Structurally similar to amphetamine; the most stimulating MAOI. Produces an alerting, sometimes euphoric effect distinct from phenelzine's anxiolytic profile. Particularly useful in psychomotor-retarded, hypersomnic depression. Insomnia is common. Activating profile can be helpful but also generates anxiety in some patients. A historic favourite among psychiatrists who have actually used it.
Transdermal selegiline — the first and only MAOI patch. At its lowest dose (6mg/24h), selectively inhibits MAO-B in the brain without significantly inhibiting intestinal MAO-A, allowing the lowest dose to be used without dietary restrictions. Higher doses require tyramine precautions. The transdermal route bypasses first-pass metabolism, producing cleaner pharmacokinetics and avoiding the peak-and-trough profile of oral administration.
Reversibly and selectively inhibits MAO-A. Because inhibition is reversible, dietary tyramine can displace moclobemide from MAO-A and be metabolised normally — greatly reducing hypertensive crisis risk. Dietary restrictions are much less stringent than with classical MAOIs (large amounts of tyramine-rich food should still be avoided). Efficacy is broadly comparable to SSRIs with a cleaner tolerability profile. Not available in the US. Less effective than classical MAOIs for severe or atypical depression but far easier to use.
The original antidepressants, introduced in the 1950s, remain among the most effective treatments for severe melancholic depression — and the most dangerous in overdose. Their pharmacological promiscuity (blocking 5-HT and NE reuptake, histamine H1, muscarinic, and alpha-1 receptors simultaneously) produces the side effects that led to their displacement by SSRIs. Yet for the right patient — particularly those with melancholic features, severe insomnia, chronic pain, or failed SSRI trials — TCAs can be transformative.
The most serotonergic TCA. The gold standard for OCD; no subsequent agent has matched its efficacy for obsessive-compulsive disorder. Also effective in severe depression with anxious features. Uniquely among antidepressants, has been reported to induce orgasm with yawning — an anecdotal but documented phenomenon. Anticholinergic burden is significant.
The original TCA and the first modern antidepressant. More noradrenergic than clomipramine. Still used for enuresis, chronic pain, and as a reference compound in research. Metabolised to desipramine.
The most prescribed TCA worldwide, largely for low-dose (10–75mg) analgesic and sleep indications. At antidepressant doses, strong antihistaminergic sedation and anticholinergic effects limit tolerability. The H1 blockade makes it effective for prophylaxis of migraine and insomnia-dominated presentations.
Active metabolite of amitriptyline. More noradrenergic, less sedating, better-tolerated than its parent compound. Has a defined therapeutic plasma window (50–150 ng/mL). Often preferred when a TCA is indicated in older adults (relatively less orthostatic hypotension and anticholinergic burden).
The past two decades have produced a generation of antidepressants that move beyond simple reuptake inhibition to engage multiple receptor systems simultaneously. These "multimodal" agents attempt to capture the anxiolytic benefits of 5-HT1A agonism, the pro-cognitive benefits of 5-HT3 and 5-HT7 receptor modulation, or the mood-brightening benefits of noradrenergic and dopaminergic enhancement — while shedding the worst side effects of older agents.
The most pharmacologically complex approved antidepressant: SSRI plus 5-HT1A agonist, 5-HT1B partial agonist, 5-HT3/7 antagonist, 5-HT1D antagonist. This receptor profile appears to confer genuine cognitive benefits (superior to duloxetine on processing speed, memory, and executive function in a meta-analysis of MDD trials) and a lower rate of sexual dysfunction and emotional blunting than SSRIs. Of particular interest for depression with prominent cognitive impairment.
A melatonin MT1/MT2 receptor agonist and 5-HT2C antagonist — a genuinely novel mechanism. Resynchronises disrupted circadian rhythms, improves sleep architecture without sedation, and via 5-HT2C blockade increases prefrontal dopamine and noradrenaline. Does not inhibit reuptake of any monoamine, which eliminates the classic SSRI side-effect spectrum. No sexual dysfunction. No discontinuation syndrome. Associated with rare hepatotoxicity; LFT monitoring required. Not available in the US.
Alpha-2 antagonism disinhibits NE and 5-HT release; potent H1 blockade provides sedation and appetite stimulation. Paradoxically more sedating at low doses (7.5–15mg) than high doses, as H1 effects dominate below the threshold where adrenergic activation kicks in. Particularly valuable in agitated, insomniac, underweight patients. Minimal sexual dysfunction. Weight gain and sedation limit tolerability in others. "Rational polypharmacy" pairing with SSRIs (California Rocket Fuel) amplifies efficacy.
Noradrenaline-dopamine reuptake inhibitor — the only licensed antidepressant with meaningful dopamine reuptake inhibition. Activating, energising, pro-sexual (uniquely among antidepressants). Licensed for smoking cessation (Zyban). Minimal weight gain; may produce weight loss. Risk of seizures at high doses; contraindicated with eating disorders. Useful in bipolar depression (lower mania switch risk than SSRIs), ADHD comorbidity, and fatigue-dominated presentations. The most "amphetamine-adjacent" mainstream antidepressant.
SSRI with 5-HT1A partial agonism — essentially a combined SSRI and buspirone in a single molecule. The 5-HT1A agonism may reduce sexual dysfunction and accelerate response onset relative to SSRIs. Requires titration with food to prevent nausea. Evidence base is smaller than SSRIs; positioned mainly as an SSRI alternative with better sexual tolerability.
An SNRI with preferential noradrenaline reuptake inhibition (3:1 NE:5-HT ratio, vs. 1:1 for duloxetine). The noradrenergic emphasis may produce greater energising effects. Positioned partly for motivation and energy deficits in depression. Modest evidence base compared to established SNRIs.
The discovery that sub-anaesthetic ketamine produces robust antidepressant effects within hours — even in patients who have failed multiple medication trials — is the most important development in psychiatry since the introduction of chlorpromazine. It overturned the monoamine hypothesis's dominance, opened glutamatergic pharmacology as a viable therapeutic domain, and offered hope to the millions for whom conventional antidepressants are insufficient.
The mechanism is incompletely understood. Ketamine is an NMDA receptor antagonist, but so is memantine — which has no antidepressant effect. The difference may lie in ketamine's action specifically during periods of neural activity (open-channel block), its affinity for synaptic versus extrasynaptic NMDA receptors, and its downstream effects: rapid BDNF release, AMPA receptor potentiation, mTOR activation, and synaptogenesis in prefrontal circuits. The metabolite (2R,6R)-hydroxynorketamine (HNK) may carry much of the antidepressant activity through AMPA-potentiating mechanisms independent of NMDA blockade.
The parent compound, used off-label for depression since the 2000 Robert Berman proof-of-concept study. Typically administered as a 40-minute IV infusion at 0.5 mg/kg, producing antidepressant effects within 24 hours that last 3–14 days. A course of 6 infusions over 3 weeks is standard. Response rates in treatment-resistant depression: 50–70%; remission rates: 20–40%. Dissociative and psychotomimetic effects during infusion are common and generally well-tolerated. Abuse potential with repeated use. The gold standard rapid-acting antidepressant by volume of evidence.
The S(+) enantiomer of ketamine; approximately 2–4× more potent at NMDA receptors. FDA-approved (2019) as an intranasal formulation for treatment-resistant depression and major depressive disorder with suicidal ideation — the first new mechanism of action approved for depression in decades. Administered in a supervised clinical setting due to dissociation and blood pressure effects. Efficacy broadly similar to IV ketamine; the intranasal route offers a more scalable delivery system. Durability remains a challenge; maintenance dosing every 1–2 weeks is often required.
A glycine-site partial agonist at NMDA receptors — potentially producing rapid antidepressant effects without dissociation. Phase 3 trials were disappointing (Allergan, 2019), but the mechanism remains pharmacologically interesting. Its failure to replicate Phase 2 results may reflect dose-finding challenges rather than mechanism invalidity. Further glycine-site modulators are in development.
A prodrug of 7-chlorokynurenic acid, an inhibitory glycine-site ligand at NMDA receptors. Oral bioavailability and selective CNS penetrance. Showed promise in early trials as an augmentation strategy with SSRIs. The kynurenine pathway is increasingly implicated in stress-related depression; this drug addresses that mechanism directly.
A long-running controversy concerns whether the dissociative/psychotomimetic effects of ketamine are necessary for its antidepressant action or merely a side effect. Some researchers argue the antidepressant response depends on the subjective experience — that the "trip" is part of the therapy, analogous to psychedelic-assisted psychotherapy. Others argue the (2R,6R)-HNK metabolite, which produces no dissociation, carries the antidepressant effect. Current evidence is mixed. Non-dissociative NMDA modulators (lanicemine, rapastinel) have largely underperformed in trials, suggesting the phenomenology may matter — or that these particular compounds lack other pharmacological features that ketamine possesses.
The neuroactive steroids represent one of the most significant conceptual advances in depression pharmacology of the past decade. These compounds are positive allosteric modulators (PAMs) of GABA-A receptors — but unlike benzodiazepines, they act at a distinct synaptic and extrasynaptic binding site and modulate both phasic and tonic GABA inhibition. Their clinical relevance emerges from the observation that neurosteroid levels — particularly allopregnanolone — fluctuate dramatically with the menstrual cycle, pregnancy, and the postpartum period, and that abrupt withdrawal of allopregnanolone following delivery is a leading neurobiological trigger of postpartum depression.
FDA-approved (2019) for postpartum depression — the first treatment specifically licensed for this condition. Administered as a continuous 60-hour IV infusion in a certified healthcare facility. Produces rapid, often profound antidepressant responses: remission rates of 50–75% in clinical trials, with effects persisting at 30-day follow-up after the single infusion. Represents proof of concept that restoring neurosteroid tone can rapidly reverse a depressive episode. Logistical burden of inpatient infusion limits use.
FDA-approved (2023): the first oral neurosteroid antidepressant and a landmark in psychiatry. A synthetic neuroactive steroid (GABA-A PAM) taken once daily for 14 days. Demonstrates rapid onset (significant separation from placebo at Day 3) with benefits persisting beyond the dosing period. Approved for major depressive disorder and postpartum depression. Sedation and dizziness are the main side effects (take at bedtime). Teratogenicity — no use in pregnancy. The 14-day course design reflects the neuroplastic mechanism: rapid induction followed by lasting structural change.
Agenapsis and Sage Therapeutics have further neurosteroid candidates in development targeting broader indications including MDD, PTSD, essential tremor, and epilepsy. PRAX-114, a selective GABA-A δ-subunit modulator, completed Phase 2 trials for MDD. The neurosteroid mechanism — modulating the set-point of inhibitory tone across the brain — offers in principle a more fundamental intervention in emotional regulation than monoamine-targeted drugs.
The psychedelic renaissance is the most consequential development in psychiatry of the early twenty-first century. After a generation of prohibition following the 1970 Controlled Substances Act, systematic clinical research into psilocybin, MDMA, LSD, and related compounds has resumed — and the results are compelling. Psychedelics produce therapeutic effects through mechanisms entirely distinct from conventional pharmacotherapy: not through chronic receptor modulation but through acute induction of neuroplastic states that, in the context of therapeutic support, appear to produce lasting changes in psychological flexibility, self-narrative, and affective default modes.
The key concept is psychoplastogen: a compound that rapidly and transiently increases neuroplasticity — the brain's capacity to reorganise — creating a window in which therapeutic change is unusually accessible. Classic psychedelics are the most powerful psychoplastogens known. Their clinical effects are therefore inseparable from the psychological context in which they are administered.
The leading psychedelic therapeutic candidate. A prodrug of psilocin, a 5-HT2A receptor agonist (with additional agonism at 5-HT2C, 5-HT1A). Phase 2/3 trials for treatment-resistant depression (COMPASS Pathways, Imperial College, Johns Hopkins) show response rates of 57–83%, remission rates of 29–36%, with effects lasting 3–12 months after 1–2 sessions. The COMP360 Phase 2b trial (n=233) showed dose-dependent antidepressant effects. FDA Breakthrough Therapy designation for both TRD and MDD. Licensed for therapeutic use in Oregon (2023), Colorado (2024), and Australia (2023). Now in Phase 3 trials.
Not a classic psychedelic but an entactogen/empathogen: massive monoamine release (5-HT ≫ DA ≈ NE) plus oxytocin release. Phase 3 trials for PTSD (MAPS) showed 67% no longer meeting PTSD diagnostic criteria vs 32% placebo, and 71% functional remission vs 48% placebo. The FDA's advisory committee voted against approval in 2024 (concerns about trial methodology, functional unblinding, and participant-therapist boundaries), and FDA rejected the NDA. Resubmission and further trials are proceeding. Australia approved MDMA-assisted therapy for PTSD in 2023. The mechanism — radical reduction of amygdala fear responses and enhancement of therapeutic alliance — is distinct from any other pharmacological intervention.
A more potent and longer-acting 5-HT2A agonist than psilocybin (effects lasting 8–12 hours vs 4–6). Clinical trials for anxiety disorders (MindMed), alcohol use disorder, and depression are proceeding. The extended duration creates logistical challenges for therapeutic protocols. Early data suggest comparable neuroplasticity induction to psilocybin. "Microdosing" LSD — sub-perceptual doses (5–15 μg) — has attracted widespread lay interest as a creativity and mood enhancer, with mixed controlled trial results (the blind is easily broken; expectancy effects are large).
The most potent known psychedelic by weight. A 5-HT1A and 5-HT2A agonist with effects lasting only 15–45 minutes (inhaled/intranasal). Produces what is often described as "ego dissolution" or "mystical unity experience" of extraordinary intensity. Retrospective surveys show large effects on measures of well-being, depression, and anxiety. Beckley Psytech and other groups are running clinical trials. The short duration makes it logistically attractive for therapeutic settings. Neuropharmacological interest focuses on its 5-HT1A component, which may produce distinct plasticity effects from classical 5-HT2A-agonist psychedelics.
An atypical psychedelic with uniquely complex pharmacology: NMDA antagonism, kappa opioid agonism, sigma receptor activity, serotonin transporter inhibition, and 5-HT2A partial agonism. Produces profound 24–36 hour experiences. Historically used for opioid detoxification (interrupts withdrawal and reduces craving via dopaminergic reset mechanisms). Recent Stanford SOCOM study of veterans showed dramatic PTSD and depression improvements. Serious cardiac risk (QTc prolongation) limits use without careful medical screening. Research into analogues (tabernanthalog, TBG) with the neuroplastic benefits but lower cardiac risk is active.
Orally active as ayahuasca (DMT + MAO-inhibiting β-carbolines from Banisteriopsis caapi). IV/inhaled DMT has been used in controlled trials. Rapid, brief psychedelic experience (inhaled DMT: 10–15 min). Observational studies and small clinical trials suggest significant antidepressant and anti-addictive effects. The β-carboline harmine in ayahuasca has independent antidepressant properties (RIMA + GSK-3β inhibitor). Dosed oral formulations (SPL026, Santo Daime protocols) are in clinical development.
The leading mechanistic hypothesis holds that psychedelics produce their lasting therapeutic effects by rapidly inducing a state of heightened synaptic plasticity — increased dendritic spine density, BDNF release, mTOR activation, AMPA receptor trafficking — during which rigid, self-reinforcing patterns of thought and affect become more malleable. This is supported by structural neuroimaging (psilocybin increases spine density in prefrontal pyramidal neurons within 24 hours in rodents) and by the clinical observation that therapeutic effects persist for months after a single administration. If this hypothesis is correct, psychedelic therapy is fundamentally not like pharmacotherapy: it is a catalyst for biological reorganisation, not a continuous molecular intervention.
Personal or family history of psychotic disorders (schizophrenia, bipolar I) is an absolute contraindication to psychedelic therapy. History of mania, severe personality disorder, and active suicidal ideation require very careful clinical judgement. Cardiovascular contraindications apply particularly to ibogaine (cardiac arrhythmia risk) and MDMA (stimulant cardiotoxicity). Set and setting are not peripheral concerns: the psychological context, therapeutic relationship, and integration support are part of the treatment mechanism. Recreational or unsupported use is qualitatively different from clinical administration.
The mood stabilisers share an empirical indication — the prevention of mood episodes in bipolar disorder — while having heterogeneous mechanisms. Their contributions to well-being pharmacology extend beyond bipolar disorder: lithium's anti-suicidal and neuroprotective properties are valuable across mood disorders; lamotrigine's glutamate-modulating properties show promise in treatment-resistant unipolar depression; lurasidone and cariprazine have robust evidence in bipolar depression.
The gold standard mood stabiliser, in continuous clinical use since 1949 and still the most effective maintenance agent for bipolar I disorder. Reduces all-cause mortality in bipolar disorder, including suicide (the only drug with robust anti-suicidal evidence across mood disorders). Neuroprotective: increases grey matter volume, promotes neurogenesis, inhibits GSK-3β (a kinase overactive in depression and neurodegeneration). Low-dose lithium (300–600mg/day, serum level 0.4–0.6 mEq/L) is increasingly used as an augmentation agent for unipolar depression and as a neuroprotectant. Narrow therapeutic index; renal and thyroid monitoring required. Environmental lithium in drinking water is inversely associated with suicide rates at the population level.
A voltage-gated sodium and calcium channel blocker that reduces glutamate release. First-line for bipolar depression and bipolar II maintenance. Unlike other mood stabilisers, does not cause metabolic syndrome, weight gain, or cognitive dulling — and many patients report improved cognitive clarity. Particularly effective against depressive pole. Slow titration required to minimise serious rash risk (Stevens-Johnson syndrome). Increasingly used off-label for treatment-resistant unipolar depression as an augmenter.
GABA enhancer, HDAC inhibitor, and glutamate inhibitor. Highly effective for mania. Teratogenic — absolute contraindication in women of childbearing potential without robust contraception (severe neural tube and neurodevelopmental effects). Significant metabolic side effects (weight gain, PCOS). Despite effectiveness, regulatory restrictions in many countries now limit use in women. Increasingly restricted in prescribing to men and postmenopausal women.
A partial agonist at D3 and D2 receptors (D3-preferring) plus 5-HT1A partial agonism. The D3 receptor modulation distinguishes it from older antipsychotics and may underlie its particular efficacy for depressive and negative symptoms. FDA-approved for bipolar depression — one of the few antipsychotics with robust evidence for bipolar depression. Activating profile; can address the prominent anhedonia and apathy of bipolar depression. Low weight gain relative to other atypicals.
FDA-approved for both schizophrenia and bipolar depression. 5-HT2A and 5-HT7 antagonist, D2 antagonist, 5-HT1A partial agonist. Low metabolic burden compared to other antipsychotics. Must be taken with food (≥350 calories) for adequate absorption. The 5-HT7 antagonism may contribute to pro-cognitive and antidepressant effects. Preferred option for many bipolar depression cases.
The stimulants occupy a peculiar position in pharmacological culture: among the most effective mood-brightening agents known, yet among the most tightly controlled, most culturally contested, and most prone to misuse. The category encompasses classical amphetamines, methylphenidate, and a newer generation of "eugeroics" — wakefulness-promoting agents with a cleaner mechanism and lower abuse potential than classical stimulants.
A prodrug of d-amphetamine that requires enzymatic cleavage in the gut wall, producing a smooth, prolonged pharmacokinetic profile with lower abuse potential than immediate-release amphetamine. First-line treatment for ADHD in many guidelines; also licensed for binge eating disorder. In ADHD, produces robust improvements in executive function, motivation, and — by reducing the cognitive chaos of ADHD — frequently marked improvements in mood. In non-ADHD depression, evidence is mixed; useful as augmentation, particularly for fatigue and anhedonia.
75% d-amphetamine, 25% l-amphetamine salt composition. The most prescribed ADHD medication in the US. Immediate-release produces a sharper onset with more pronounced peripheral effects and euphoric potential; XR formulation is preferred for clinical use. Pro-dopaminergic, pro-noradrenergic: potent motivation enhancer. Cardiovascular monitoring and blood pressure checks necessary. The euphoric and productivity-enhancing effects have driven enormous non-prescribed use in competitive academic and professional environments — an uncontrolled experiment whose long-term consequences remain incompletely understood.
A dopamine and noradrenaline reuptake inhibitor — mechanistically more similar to cocaine (but slower onset) than to amphetamine. Standard first-line for ADHD in many European countries. Lower abuse potential than amphetamine due to slower CNS penetration rate. Multiple extended-release formulations optimise coverage. In palliative and medical settings, used as a rapid-acting antidepressant and anti-fatigue agent.
A wakefulness-promoting agent with a partially understood mechanism — primarily a weak dopamine transporter inhibitor, but also activating histaminergic, orexinergic, and noradrenergic systems. FDA-approved for narcolepsy, shift work disorder, and sleep apnoea. Widely used off-label for cognitive enhancement, fatigue, and depression augmentation. Lower abuse potential than amphetamines (slow onset, limited euphoria). Induces CYP3A4/CYP2C19 — significant drug interactions. Particularly useful for SSRI-induced fatigue and for the sedating depression phenotype. Consistently top-rated by users for general cognitive enhancement relative to side-effect burden.
The R-enantiomer of modafinil; longer half-life, producing more sustained effects than the racemate with a similar or slightly lower dose. Some users prefer its pharmacokinetic profile for sustained afternoon alertness. Licensed for the same indications as modafinil.
A histamine H3 receptor antagonist/inverse agonist that increases histamine, acetylcholine, dopamine, and noradrenaline release. Non-scheduled; FDA-approved for narcolepsy with and without cataplexy. Pro-cognitive via histaminergic and cholinergic mechanisms. Absent the abuse potential of classical stimulants. A promising addition to the eugeroic armamentarium, particularly for patients who cannot tolerate modafinil-related side effects or for whom scheduling constraints matter.
A dual DA/NE reuptake inhibitor — mechanistically intermediate between modafinil and methylphenidate. Schedule IV. Approved for narcolepsy and sleep apnoea-associated daytime sleepiness. Linear dose-response for wakefulness. May be useful in ADHD and depression-related fatigue; studies ongoing.
GABA-A positive allosteric modulators. The most effective short-term anxiolytics available. Rapid onset, reliable anxiolysis, muscle relaxation, anticonvulsant activity. Tolerance develops within weeks for anxiolytic effects; dependence and withdrawal syndrome after sustained use can be severe and protracted. The place of benzodiazepines in anxiety pharmacotherapy has been radically restricted, but they remain irreplaceable for acute anxiety management, alcohol withdrawal, status epilepticus, and procedural sedation. Long-acting agents (diazepam, clonazepam) have less abuse potential and smoother pharmacokinetics than short-acting ones (alprazolam, triazolam). The abolitionist perspective notes that benzodiazepines suppress suffering without eliminating its cause — a blunting, not a cure.
Alpha-2-delta calcium channel subunit ligand — reduces presynaptic excitatory neurotransmitter release. Licensed for GAD, neuropathic pain, and fibromyalgia. Rapid anxiolytic onset (1–2 weeks). Abuse potential has emerged as a concern, particularly in populations with history of substance use disorders. Distinct from gabapentin (superior pharmacokinetics, more consistent absorption). Sedation and dizziness are common initial side effects.
A 5-HT1A partial agonist (and weak D2/D3 partial agonist). Non-sedating, non-addictive anxiolytic. Requires 2–4 weeks for full effect — unlike benzodiazepines. Effective in GAD; less effective for acute anxiety or panic disorder. No cross-tolerance with benzodiazepines (cannot substitute for them in dependence). Low side-effect burden makes it a rational long-term GAD treatment. Frequently underused because the delayed onset leads patients (and clinicians) to abandon it prematurely.
A first-generation antihistamine with anxiolytic, antiemetic, and mild sedative effects via H1 and muscarinic blockade. Rapid anxiolytic effects (within 30 minutes). Non-scheduled, no dependence or withdrawal. Useful for acute anxiety when benzodiazepines are contraindicated (substance use history, cognitive impairment). Anticholinergic burden limits use in elderly patients.
The kappa opioid system has emerged as one of the most exciting targets in depression and anxiety pharmacology. Kappa opioid receptors (KORs), activated by endogenous dynorphins, mediate dysphoria, stress hypersensitivity, anhedonia, and the aversive quality of emotional pain. Sustained activation of the dynorphin-KOR system by chronic stress is now understood to be a key driver of depressive anhedonia — the loss of the capacity to feel pleasure. Blocking KOR activation therefore offers a potential path to restoring hedonic capacity that is mechanistically distinct from all existing antidepressants.
Classical KOR antagonists (JDTic, norBNI) had extremely prolonged receptor occupancy (weeks to months), making dosing problematic. The newer "short-acting" KOR antagonists — aticaprant, navacaprant — have overcome this pharmacological limitation and are in late-stage clinical development.
A selective, short-acting KOR antagonist. Demonstrated antidepressant and anti-anhedonia effects in Phase 2 trials, particularly in patients with high baseline anhedonia and elevated depression biomarkers. Johnson & Johnson/Janssen conducted Phase 2b/3 trials for MDD with anhedonia and for adjunctive treatment of inadequate SSRI response. The anhedonia-specific profile makes it potentially the first agent targeting the pleasure-deficit dimension of depression directly. Phase 3 programme ongoing as of 2026.
Another short-acting, selective KOR antagonist in clinical development (Black Bear Bio / Neumora Therapeutics). Phase 2 data showed antidepressant effects and an interesting signal on anhedonia measures. One study suggested benefit in a subgroup defined by high anhedonia scores and elevated plasma CRP (inflammatory marker), pointing toward precision psychiatry applications.
From a Pearcean perspective, the kappa opioid system is uniquely important. KOR activation by dynorphins is not merely a pharmacological curiosity: it is the molecular substrate of much of the aversive, dysphoric suffering that characterises stress states. The dynorphin-KOR system evolved to generate the aversive valence of pain and deprivation — to motivate avoidance. In a world where avoidance is no longer needed, or where suffering cannot be escaped, this system produces meaningless misery. KOR antagonism represents a targeted assault on the neurochemistry of suffering rather than a blunt elevation of positive affect.
The endogenous opioid system is the primary molecular substrate of hedonic experience. Mu opioid receptor activation produces warmth, contentment, social comfort, and relief from pain — physical and emotional. This system evolved to signal successful consummation of goals (food, sex, social bonding). Its pharmacological modulation is therefore directly relevant to the pursuit of well-being enhancement, even as clinical opiophobia has made this one of the most politically charged areas in medicine.
Buprenorphine is a partial agonist at mu opioid receptors and an antagonist at kappa opioid receptors. This dual profile — activating the hedonic system while blocking its dysphoric counterpart — gives buprenorphine a unique pharmacological signature for depression. At sub-addiction doses (0.1–0.5mg sublingual), buprenorphine has shown rapid, robust antidepressant effects in treatment-resistant depression trials (Nierenberg et al., others). The AZ-002 (BRIXIA) programme (buprenorphine/samidorphan combination) demonstrated sustained antidepressant effects without addiction liability. The opioid crisis has severely constrained clinical enthusiasm, but buprenorphine's antidepressant potential is pharmacologically compelling.
At 1/10th of the standard opioid-antagonist dose, naltrexone transiently blocks opioid receptors, triggering a homeostatic upregulation of endogenous opioid production (endorphins, enkephalins). This rebound increase in opioid tone, plus direct Toll-like receptor 4 (TLR4) antagonism (anti-inflammatory), produces analgesic, anti-inflammatory, and mood-brightening effects in numerous conditions including fibromyalgia, Crohn's disease, chronic fatigue, and depression. Remarkably safe. A rapidly growing evidence base supports its utility despite the absence of pharmaceutical sponsorship (the patent has expired). One of the most underutilised agents in this guide.
A mu opioid receptor agonist with antidepressant properties, paradoxically: historically misclassified as a "serotonin reuptake enhancer" (an artefact of its development context). Effective antidepressant with rapid onset. Widely used in France and Eastern Europe. Significant abuse potential — "gas station heroin" in the US (sold as a supplement where unscheduled; increasingly scheduled). Illustrates the potential and peril of opioid-based antidepressants.
Trace amine-associated receptor 1 (TAAR1) is a G-protein-coupled receptor expressed in monoaminergic neurons of the limbic system, dorsal raphe, locus coeruleus, and ventral tegmental area. It functions as a presynaptic autoreceptor and heteroreceptor that modulates dopamine, serotonin, and noradrenaline tone without directly stimulating these systems. TAAR1 agonists are therefore mechanistically unprecedented: they modulate monoamine systems indirectly, with a potentially more refined signal than reuptake inhibitors or direct receptor agonists.
The result, in clinical trials, is a remarkably clean pharmacological profile: antipsychotic, antidepressant, pro-cognitive, anti-addictive effects without the metabolic syndrome burden of D2 antagonists or the sexual dysfunction and emotional blunting of SSRIs. TAAR1 may be the most important new antidepressant mechanism discovered since the glutamatergic hypothesis.
A TAAR1 agonist and 5-HT1A partial agonist developed by Sunovion (Sumitomo). FDA Breakthrough Therapy designation for schizophrenia. Phase 3 results in schizophrenia showed significant improvements in positive, negative, and cognitive symptoms without significant weight gain, metabolic effects, or extrapyramidal side effects. Phase 2 trials in MDD are ongoing. The drug represents the possibility of treating mood and psychosis without D2 blockade — the mechanism underlying virtually all current antipsychotics.
A highly selective TAAR1 agonist (no 5-HT1A activity) from Roche. Early clinical studies in schizophrenia. The selectivity allows cleaner dissection of TAAR1-specific effects. Phase 2 trials ongoing for depression and binge eating disorder. A research tool as much as a drug candidate.
The neuroplasticity model of depression — in which the core pathology is insufficient synaptic connectivity in prefrontal circuits, not a simple monoamine deficit — has refocused drug development on agents that promote BDNF signalling, synaptogenesis, and neural circuit remodelling. Psychedelics are the most powerful known psychoplastogens. But a pharmacological pipeline of agents targeting BDNF/TrkB signalling more directly is advancing.
A small-molecule neurogenic compound (benzylpiperazine-aminopyridine) that increases hippocampal volume and BDNF expression in rodents. Phase 1b trials showed promising antidepressant effects and improved cognition; Phase 2 trial (Neuralstem) showed statistically significant cognitive improvements but the primary antidepressant endpoint was not met at the pre-specified significance level. The compound continues to attract interest as a procognitive antidepressant adjunct. Available through research grey markets; formally in development limbo.
BDNF (Brain-derived neurotrophic factor) acts through TrkB receptors to promote synaptic growth and neuronal survival. Direct small-molecule TrkB agonists are being developed. Psilocybin appears to bind TrkB directly (as well as 5-HT2A), possibly contributing to its plasticity effects independent of the psychedelic experience. The identification of BDNF-TrkB as a shared downstream effector of virtually all antidepressant treatments suggests TrkB agonism could be the common final mechanism — and its direct targeting a pharmacological shortcut.
Synthetic peptide analogues of ACTH (Semax) and tuftsin (Selank). Widely used in Russia as registered medicines; available online in the West as research chemicals. Semax increases BDNF and VEGF; Selank has anxiolytic and nootropic effects via enkephalinase inhibition and GABA modulation. Small-scale trials show cognitive and anxiolytic benefits. The evidence base is modest by Western regulatory standards but the compounds have a long track record of clinical use in Eastern Europe.
The GLP-1 receptor agonists — semaglutide, liraglutide, tirzepatide — were developed for diabetes and obesity. Their psychiatric effects were initially noticed as an observation: patients reported not merely weight loss but a profound reduction in food preoccupation, addictive cravings, and — unexpectedly — improvements in mood and anxiety. Large real-world datasets now confirm lower rates of depression, anxiety, and suicidal ideation in GLP-1 agonist users compared to matched controls.
GLP-1 receptors are expressed in limbic and hypothalamic circuits. The mechanism of mood benefit likely involves multiple pathways: reduction of neuroinflammation, direct dopaminergic modulation (GLP-1 receptors in the VTA and nucleus accumbens), and — most intriguingly — a general reduction in what might be called "wanting without pleasure": the compulsive motivational state that characterises addiction, binge eating, and the hyperreactive reward system of depression. Clinical trials for alcohol use disorder, nicotine dependence, and MDD are underway. This is one of the most surprising pharmacological discoveries of the mid-2020s.
GLP-1 receptor agonist; the dominant agent in the class by 2026. Large observational datasets show reduced rates of depression, suicidal ideation, alcohol use disorder, opioid misuse, and tobacco use. RCTs for psychiatric indications are in progress. The psychiatric effects appear partly independent of weight loss. If the mood benefits are confirmed in clinical trials, semaglutide will represent a genuinely novel antidepressant mechanism — and one with broad metabolic benefits as a co-benefit.
The nootropic category is heterogeneous and scientifically uneven. It ranges from well-established compounds with robust evidence (caffeine, modafinil) through modestly evidence-based nutraceuticals to speculative compounds with minimal human data. The following covers the most evidence-supported options outside the prescription categories already discussed.
The world's most used psychoactive drug. Adenosine receptor antagonist: blocks A1 and A2A receptors, disinhibiting dopamine release. Established cognitive enhancer (attention, reaction time, working memory). Associated in large epidemiological studies with reduced risk of depression, Parkinson's disease, and Alzheimer's disease. The dose-response for well-being is an inverted U: modest doses enhance mood and cognition; high doses produce anxiety and insomnia. Adenosine receptor antagonism is the mechanism through which exercise may confer cognitive protection. The most underrated substance in this guide.
The original nootropic class, discovered by Corneliu Giurgea in the 1960s. Mechanisms include AMPA receptor positive allosteric modulation (which also underlies part of the antidepressant mechanism of ketamine and psychedelics), acetylcholine facilitation, and membrane fluidity effects. Piracetam has the largest evidence base and is a licensed medicine in Europe for cognitive disorders. Cognitive enhancement in healthy individuals is modest. The racetam class illustrates a general principle: AMPA potentiation enhances synaptic plasticity and may have broad pro-cognitive and mood-brightening effects.
Nicotinic acetylcholine receptor agonist. In isolation from tobacco — via patch or gum — nicotine is a cognitively and subjectively enhancing drug with a favourable risk profile. Improves attention, working memory, processing speed. Protective against Parkinson's disease and ulcerative colitis in epidemiological studies. Low-dose nicotine patches (3.5–7mg) are used by a growing number of healthy individuals as cognitive enhancers. Dependence potential is lower without the tobacco delivery vehicle, which provides addiction-reinforcing cues. Cardiovascular effects (transient increase in heart rate and blood pressure) warrant caution in pre-existing cardiac disease.
A phosphocreatine precursor. Well-established ergogenic and muscle-building supplement. Growing evidence for cognitive and mood benefits: creatine supplementation improves working memory, reduces fatigue in sleep-deprived states, and has shown antidepressant effects in several trials (particularly in women with MDD). Mechanism relates to brain energy metabolism: creatine buffers ATP in high-demand neurons. Safe, cheap, and widely available. One of the most evidence-supported supplements in this guide for both physical and cognitive well-being.
The following compounds are available without prescription in most jurisdictions and have meaningful evidence bases for mood and cognitive support. Expectations should be calibrated: their effect sizes are generally smaller than prescription antidepressants, but their safety profiles are often superior, and for mild-to-moderate mood disorders they represent a reasonable first step.
| Compound | Mechanism | Evidence Level | Notes |
|---|---|---|---|
| Omega-3 (EPA/DHA) | Anti-inflammatory; neuronal membrane fluidity; serotonergic modulation | Moderate: meta-analyses support adjunctive use in MDD (EPA ≥ 60% of formulation preferred) | 2–3g/day EPA-dominant formulation; safe; anti-cardiovascular co-benefit |
| SAMe (S-adenosyl-methionine) | Methyl donor; enhances monoamine synthesis; anti-inflammatory | Good: Cochrane review shows superiority to placebo in MDD; comparable to TCAs in some trials | 400–1600mg/day; expensive; may precipitate hypomania in bipolar |
| N-Acetylcysteine (NAC) | Glutathione precursor; antiglutamatergic; anti-inflammatory; modulates cystine-glutamate transporter | Moderate: positive trials in bipolar depression, OCD, addiction; mixed MDD data | 1800–3600mg/day; safe; acetaminophen overdose antidote co-benefit |
| Saffron (Crocus sativus) | Serotonin reuptake inhibition; NMDA modulation; antioxidant | Good: multiple RCTs show antidepressant efficacy comparable to SSRIs at low doses (30mg/day) | 30mg/day standardised extract; safe; anti-inflammatory; culinary history |
| Magnesium | NMDA receptor co-factor; HPA axis regulation; deficiency associated with depression | Moderate: deficiency is common (40% of US population); supplementation trials show benefit in deficient individuals | 200–400mg/day (glycinate or malate preferred); excellent safety; sleep benefits |
| Lithium orotate | Same as lithium carbonate; orotate salt claimed to cross BBB more readily at lower doses | Limited clinical RCTs; strong mechanistic rationale; population data (water lithium) compelling | 5–20mg/day; far below clinical prescription doses; theoretically neuroprotective |
| Vitamin D | Modulates serotonin synthesis; neuroprotective; immune modulation | Moderate: meta-analyses show benefit in deficient patients; less clear in replete populations | 1000–4000 IU/day; deficiency is epidemic in northern latitudes; safe; check 25-OH-D3 levels |
| Rhodiola rosea | Adaptogen; monoamine oxidase inhibition; cortisol regulation | Moderate: positive RCTs for mild-moderate depression, burnout, fatigue | 400–600mg/day (standardised to rosavins/salidroside); stimulating; not at night |
| Ashwagandha (KSM-66) | Cortisol reduction (HPA modulation); GABAergic; thyroid modulation | Good: multiple RCTs show significant cortisol reduction, anxiolytic effects, cognitive benefits | 300–600mg/day; well-tolerated; particularly good for stress/anxiety phenotype |
| Curcumin (Theracurmin/BCM-95) | Anti-inflammatory (NF-κB inhibition); BDNF induction; MAO inhibition | Moderate: RCTs show antidepressant effects; bioavailability of standard forms is poor (use enhanced formulations) | 500–2000mg/day (bioavailable form); safe; anti-inflammatory co-benefits; weak CYP3A4 inhibition |
Every drug discussed in this guide is a temporary intervention. Even the most effective psychedelics produce effects lasting months, not years. Even lithium, taken continuously for decades, is managing rather than curing. The fundamental challenge is that the hedonic set-point — the attractor state to which mood reliably returns — is substantially genetically determined. Pharmacology can perturb it; only changing the genome can move it.
This is no longer science fiction. CRISPR-Cas9 and related base-editing and prime-editing technologies are capable, in principle, of targeting the genetic variants associated with chronic low hedonic tone. Genome-wide association studies of subjective well-being (Okbay et al., de Vlaming et al., Baselmans et al.) have identified hundreds of genetic loci associated with positive affect, life satisfaction, and depression. The effect sizes of individual loci are small — typical OR 1.02–1.05 — but polygenic scores for well-being explain 5–10% of variance and are improving rapidly as sample sizes grow.
The path from GWAS hits to therapeutic genome editing is long. Several challenges must be overcome:
Preimplantation genetic testing for polygenic conditions (PGT-P) is already commercially available for height, IQ, and disease risk. The extension to polygenic well-being scores is a small step technically, though a large one ethically and socially. IVF-conceived embryos could in principle be screened for polygenic well-being scores and those in the upper distribution preferentially selected. The expected gain per round of selection is modest (perhaps 0.2–0.5 standard deviations of well-being, depending on embryo number and score distribution), but the intervention is safe, voluntary, and permanent.
Beyond editing the genome, gene therapy approaches can transiently or permanently alter gene expression in specific brain circuits:
Deep brain stimulation (DBS) of the subgenual anterior cingulate cortex (Area 25, sgACC) has shown dramatic results in small trials of ultra-treatment-resistant depression. Next-generation DBS systems are "closed-loop": they continuously monitor biomarkers of mood state (local field potentials, spectral power in gamma/beta bands) and adjust stimulation parameters in real time to maintain therapeutic tone. This represents the most sophisticated pharmacological-independent mood regulation technology available — and, as miniaturisation proceeds, the possibility of embedded, always-on mood regulation devices enters the domain of serious consideration.
This guide began with the observation that the biosphere runs on suffering. It ends with the observation that, for the first time in the history of life on Earth, the tools exist — pharmacological, neurochemical, genomic — to fundamentally revise that equation. The suffering catalogued in every edition of the DSM is not a metaphysical necessity. It is a biological legacy that a sufficiently advanced civilisation has the power to address.
The drugs described in this guide are imperfect, partial instruments of a project that is larger than any of them. SSRIs reduce suffering; they do not eliminate it. Ketamine produces hours of remission; it does not yet produce decades of well-being. Psilocybin opens windows of psychological possibility; it does not guarantee the person who walks through them will find flourishing on the other side. The gap between what is possible pharmacologically and what is required for the abolition of suffering is still vast.
But the trajectory is clear. Each year, the understanding of the neurochemistry of suffering deepens. Each year, the tools for modifying it become more precise. Zuranolone — a 14-day oral course that produces rapid, lasting antidepressant effects through a mechanism entirely different from anything available in 2000 — was impossible to imagine in 1990. The TAAR1 agonists, KOR antagonists, and neuroplasticity inducers now entering late-stage trials were theoretical proposals a decade ago. The genomic tools now available in research settings were science fiction in 2010.
The goal of this guide is not merely to help the reader navigate the pharmacopeia of 2026. It is to situate that pharmacopeia within a larger project: the project of using human intelligence to redesign the emotional architecture of sentient life. That project will not be completed by any single drug, any single trial, or any single generation. But it is underway. And it is, arguably, the most important work that any generation has ever undertaken.
A note on evidence ratings: Numerical ratings in this guide (Efficacy, Tolerability, Well-being+) are composite qualitative assessments based on clinical trial data, meta-analyses, and clinical experience, scaled 0–10. They are not derived from formal meta-analytic calculations and should not be quoted as such. They are intended as orientation guides rather than precise empirical claims.
Conflicts of interest: This guide was written without pharmaceutical industry sponsorship. No financial relationships with manufacturers of any compound discussed existed at the time of writing.
Currency: Psychopharmacology is a rapidly evolving field. Information was current to early 2026. Readers should consult primary literature, regulatory agencies (FDA, EMA, TGA), and clinical guidelines for the most current data.
Attribution: This guide is a successor to The Good Drug Guide originally published on biopsychiatry.com, which was associated with the work of philosopher David Pearce. The philosophical framework of hedonic imperative and abolitionism derives from Pearce's writings, particularly The Hedonistic Imperative (1995) and The Abolitionist Project.